Repatha generic name
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Repatha Generic Name: Evolocumab
Introduction to Evolocumab (Repatha)
Evolocumab, marketed under the brand name Repatha, is a fully human monoclonal antibody developed by Amgen. It has been approved for the treatment of hypercholesterolemia in various regions, including the European Union, and is awaiting approval in other countries such as the USA and Japan.
Mechanism of Action: PCSK9 Inhibition
Evolocumab works by specifically binding to proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a negative regulator of low-density lipoprotein (LDL) receptors. By inhibiting PCSK9, evolocumab enhances the liver's ability to bind LDL-cholesterol (LDL-C), which leads to a reduction in LDL-C levels in the blood.
Clinical Applications
Evolocumab is used to reduce LDL-C levels in patients with hypercholesterolemia. It can be administered as monotherapy or in combination with statins and other lipid-lowering therapies. The drug is particularly beneficial for patients whose hypercholesterolemia is not adequately controlled by statins alone .
Indications
Evolocumab is indicated for:
- Adults with primary hypercholesterolemia (both heterozygous familial and non-familial) or mixed dyslipidemia as an adjunct to diet, with or without statins and/or other lipid-lowering therapies.
- Adults and adolescents aged 12 years and older with homozygous familial hypercholesterolemia, in combination with other lipid-lowering therapies.
Conclusion
Evolocumab (Repatha) represents a significant advancement in the treatment of hypercholesterolemia, particularly for patients who do not achieve desired LDL-C levels with statins and other therapies. By targeting PCSK9, evolocumab offers a novel mechanism to effectively lower LDL-C levels and improve cardiovascular health outcomes .
Sources and full results
Most relevant research papers on this topic